Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670997 | 1.00 | EPHX1 (0.50) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL5732556 | 1.00 | EPHX1 (0.50) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL3870627 | 1.00 | EPHX1 (0.50) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL4912039 | 1.00 | EPHX1 (0.50) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL1683190 | 1.00 | EPHX1 (0.50) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL6562522 | 1.00 | EPHX1 (0.50) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2799200 | 0.88 | EPHX1 (0.42) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL10403496 | 0.86 | EPHX1 (0.41) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL4607825 | 0.84 | LTA4H (0.57) | SLC6A2MAOASLC6A3SIGMAR1PTGS1 | |
| SCHEMBL1817589 | 0.84 | LTA4H (0.57) | SLC6A2MAOASLC6A3SIGMAR1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067125-B1 | PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES | KANEKA CORP (JP) | 2006-07-26 | — | — | EP | claimed |
| EP-1661893-A2 | Process for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives | Kaneka Corporation (JP) | 2006-05-31 | — | — | EP | claimed |
| US-6344572-B1 | BASIFICATION OF 1-HALO-2-HYDROXY-3-AMINO-PHENYLBUTANE IN SOLVENT AND ADDING MIXTURE TO WATER TO CRYSTALLIZE IT | KANEKA CORPORATION (JP) | 2002-02-05 | — | — | US | claimed |
| EP-1067125-A1 | PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES | KANEKA CORPORATION (JP) | 2001-01-10 | — | — | EP | claimed |
| US-5936104-A | Process for producing 1,2-epoxy-3-amino-4-phenylbutane derivatives | KANEKA CORPORATION (JP) | 1999-08-10 | — | — | US | claimed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-0901480-A4 | PROCESS FOR PREPARING OXIRANEMETHANAMINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5936104-A | Process for producing 1,2-epoxy-3-amino-4-phenylbutane derivatives | KANEKA CORPORATION (JP) | 1999-08-10 | — | — | US | disclosed |
| US-5936104-A | Process for producing 1,2-epoxy-3-amino-4-phenylbutane derivatives | KANEKA CORPORATION (JP) | 1999-08-10 | — | — | US | disclosed |
| US-5936104-A | Process for producing 1,2-epoxy-3-amino-4-phenylbutane derivatives | KANEKA CORPORATION (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0901480-A1 | PROCESS FOR PREPARING OXIRANEMETHANAMINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5847169-A | Process for preparing oxiranemethanamine derivatives | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997042180-A1 | PROCESS FOR PREPARING OXIRANEMETHANAMINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | EPHX1 414/4885SLC6A2 4281/4885TAAR1 4375/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | EPHX1 414/4885SLC6A2 4281/4885TAAR1 4375/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | EPHX1 414/4885SLC6A2 4281/4885TAAR1 4375/4885 |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | EPHX1 414/4885SLC6A2 4281/4885TAAR1 4375/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | EPHX1 236/4885SLC6A2 4600/4885TAAR1 4512/4885 |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | EPHX1 229/4885SLC6A2 4581/4885TAAR1 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.